Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer

PURPOSE: Sequential drug treatments in metastatic breast cancer (MBC) are disparate. Clinical trial data includes limited reporting of treatment context, primarily including the number of prior therapies. This study evaluates the relationship between prior treatment time, prior lines of treatment, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocque, Gabrielle B., Gilbert, Aidan, Williams, Courtney P., Kenzik, Kelly M., Nakhmani, Arie, Kandhare, Pravinkumar G., Bhatia, Smita, Burkard, Mark E., Azuero, Andres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444642/
https://www.ncbi.nlm.nih.gov/pubmed/32479187
http://dx.doi.org/10.1200/CCI.20.00008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444642/
https://www.ncbi.nlm.nih.gov/pubmed/32479187
http://dx.doi.org/10.1200/CCI.20.00008

Ejemplares similares